Releases Details

Result of AGM

Oct 29, 2021

GAITHERSBURG, Md., Oct. 29, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, announces that at its Annual General Meeting held on 29th October 2021, all resolutions were duly passed, with the exception of Proposal 2, relating to the approval of the 2021 Equity Incentive Plan.

About MaxCyte

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation® platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: three instruments, the ATx™, STx™ and GTx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

MaxCyte Contacts:

US IR Adviser
Gilmartin Group
David Deuchler, CFA

+1 415-937-5400
 ir@maxcyte.com
   
US Media Relations
Laura Morgan
Sam Brown Healthcare Communications

+1 951-333-9110
lauramorgan@sambrown.com
   
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden

+44 (0)20 7886 2500
   
UK IR Adviser
Consilium Strategic Communications
Mary-Jane Elliott
Chris Welsh

+44 (0)203 709 5700
maxcyte@consilium-comms.com